A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia - Byrd, John C.; Pagel, John M.; Awan, Farrukh T.; Forero, Andres; Flinn, Ian W.; Deauna-Limayo, Delva P.; Spurgeon, Stephen E.; Andritsos, Leslie A.; Gopal, Ajay K.; Leonard, John P.; Eisenfeld, Amy J.; Bannink, Jeannette E.; et al. (Blood, 2014)
Keywords: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - adverse effects; Antigens, Neoplasm - immunology; Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Clinical Trials and Observations; Female; Humans; Immunoglobulin G - adverse effects; Immunoglobulin G - therapeutic use; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Male; Maximum Tolerated Dose; Middle Aged; Protein Engineering; Recombinant Fusion Proteins - adverse effects; Recombinant Fusion Proteins - therapeutic use; Tetraspanins - immunology; Treatment Outcome